Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Liabilities and Shareholders Equity (2024 - 2025)

Historic Liabilities and Shareholders Equity for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $649.4 million.

  • Kura Oncology's Liabilities and Shareholders Equity rose 3561.63% to $649.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year change of. This contributed to the annual value of $760.2 million for FY2024, which is N/A changed from last year.
  • Kura Oncology's Liabilities and Shareholders Equity amounted to $649.4 million in Q3 2025, which was up 3561.63% from $682.4 million recorded in Q2 2025.
  • Kura Oncology's Liabilities and Shareholders Equity's 5-year high stood at $760.2 million during Q4 2024, with a 5-year trough of $478.8 million in Q3 2024.